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Abstract
Background: Multiple national expert panels have identified early detection of Alzheimer’s disease and related
dementias (ADRD) as a national priority. However, the United States Preventive Services Task Force (USPSTF) does
not currently support screening for ADRD in primary care given that the risks and benefits are unknown. The
USPSTF stresses the need for research examining the impact of ADRD screening on family caregiver outcomes.
Methods: The Caregiver Outcomes of Alzheimer’s Disease Screening (COADS) is a randomized controlled trial that
will examine the potential benefits or harms of ADRD screening on family caregivers. It will also compare the
effectiveness of two strategies for diagnostic evaluation and management after ADRD screening. COADS will enroll
1800 dyads who will be randomized into three groups (n = 600/group): the ‘Screening Only’ group will receive
ADRD screening at baseline and disclosure of the screening results, with positive-screen participants receiving a list
of local resources for diagnostic follow-up; the ‘Screening Plus’ group will receive ADRD screening at baseline
coupled with disclosure of the screening results, with positive-screen participants referred to a dementia
collaborative care program for diagnostic evaluation and potential care; and the control group will receive no
screening. The COADS trial will measure the quality of life of the family member (the primary outcome) and family
member mood, anxiety, preparedness and self-efficacy (the secondary outcomes) at baseline and at 6, 12, 18 and
24 months. Additionally, the trial will examine the congruence of depressive and anxiety symptoms between older
adults and family members at 6, 12, 18 and 24 months and compare the effectiveness of two strategies for
diagnostic evaluation and management after ADRD screening between the two groups randomized to screening
(Screening Only versus Screening Plus).
Discussion: We hypothesize that caregivers in the screening arms will express higher levels of health-related
quality of life, lower depressive and anxiety symptoms, and better preparation for caregiving with higher self-
efficacy at 24 months. Results from this study will directly inform the National Plan to Address Alzheimer’s Disease,
the USPSTF and other organizations regarding ADRD screening and early detection policies.
Trial registration: ClinicalTrials.gov, NCT03300180. Registered on 3 October.
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Introduction
There are currently 5.4 million adults with Alzheimer’s
disease and related dementias (ADRD) and 11 million in-
formal caregivers in the USA [1], potentially rising to 13.8
and 27 million, respectively by 2050 [2, 3]. Currently, at
least 50% of patients with ADRD are undiagnosed and,
among those who are diagnosed, only half of the patients
or their families know of the diagnosis [4–7]. Further-
more, the diagnosis often occurs 2–5 years after the onset
of symptoms [8–11]. Although the United States Prevent-
ive Services Task Force (USPSTF) recommendations do
not currently support screening for ADRD in primary care
[12], multiple national expert panels who represent a
broad range of stakeholders have identified early detection
of ADRD as a national priority. Specifically, the National
Academy of Science, the National Plan to Address Alzhei-
mer’s Disease, and the Affordable Care Act (via the Medi-
care Annual Wellness Visit (AWV)) all identify earlier
detection of ADRD as a core aim for improving the quality
of care for older adults [13–15].
Of those patients with ADRD living in the community,
75% are cared for by family caregivers [16–18] and
treated in primary care settings [19–21]. Barriers that
lead to a delay in diagnosis can potentially lead to poorer
patient and family caregiver outcomes [5, 6, 8, 22–24].
For example, delayed diagnosis perpetuates the belief
that changes in cognition are part of “normal aging”,
which has been shown to aggravate caregivers’ stress,
burden and sense of isolation [22, 24, 25]. Furthermore,
family members may not notice their own changing role,
leaving them vulnerable or unprepared to become a
caregiver [22, 26]. The USPSTF found no studies linking
ADRD screening to improved family caregiver outcomes
and stressed the need for research in this area [12, 27].
Those recommending earlier detection of ADRD believe
that screening will: 1) increase opportunities for earlier
medical, social, and advance care planning interventions;
2) identify and name the early cognitive, functional, psy-
chological or behavioral symptoms as abnormal aging;
and 3) provide an opportunity for family members to learn
about the syndrome, prepare for the caregiver role, and
plan for future care needs [5, 28–31]. The USPSTF has ex-
plicitly acknowledged the potential importance of identify-
ing early cognitive impairment for family members and
caregivers [12]. Thus, proactive approaches to early ADRD
detection may improve the quality of life for family mem-
bers who may ultimately become caregivers for their loved
ones [19, 20, 29, 32]. The Medicare AWV came into effect
in 2011 and includes detection of cognitive impairment as
one of the annual routine assessments, citing these puta-
tive benefits [15]. In 2014, ≤14% of eligible beneficiaries
received the AWV [33]. Analyses of the impact of the
AWV on cognitive detection or care found that the AWV
is correlated with an increase in some measures of
cognitive care, such as laboratory testing for reversible
causes for cognitive impairment, but it does not appear to
have a substantial impact on improving the recognition of
undetected ADRD [33].
Those who do not recommend routine ADRD screening
believe that, without effective treatments, the emotional
and social costs of screening are too high [34, 35]. For
example, in a survey of 576 family members, caregivers for
individuals who had received an ADRD diagnosis reported
more relationship strain and reduced social activities com-
pared with caregivers for individuals who had no official
diagnosis, independent of the level of patient impairment
[36]. These results imply that receiving a diagnosis once
symptoms have emerged may elevate the importance of
the disease, making it a more prominent part of an indi-
vidual’s role and identity and perhaps prompting care-
givers to become overly focused on providing personal
care to the exclusion of their own well-being.
In response to these gaps in the knowledge base, our re-
search team is conducting a randomized controlled trial,
the Caregiver Outcomes of Alzheimer’s Disease Screening
(COADS) study, to examine if ADRD screening impacts
family member quality of life, depression and anxiety
while controlling for detection that may occur as part of
routine primary care or the AWV. The primary outcome
in COADS is caregivers’ health-related quality of life; sec-
ondary outcomes are caregiver depression, anxiety, pre-
paredness, and caregiving self-efficacy. We hypothesize
that family members randomized to one of two screening
arms will express higher levels of health-related quality of
life, lower rates of depressive and anxiety symptoms, and
report themselves to be more prepared for caregiving with
higher self-efficacy at 24months as compared to the con-
trol group without screening. Secondarily, the study will
also examine the congruence of depressive and anxiety
symptoms between older adults and family members and
compare the effectiveness of two strategies for diagnostic
evaluation and management after Alzheimer’s disease
screening between dyads randomized to the two screening
groups (‘Screening Only’ versus ‘Screening Plus’). Re-
sults from this study will directly inform the National
Plan to Address Alzheimer’s Disease, the USPSTF and
other organizations regarding their ADRD screening
and early detection policies.
Methods
Study design
The COADS study is a multicenter, three-arm, random-
ized controlled trial. The aims of the study are to evalu-
ate the impact of ADRD screening on family members’
quality of life, mood and anxiety. Additionally, the study
will assess the impact of ADRD screening on family
members’ caregiving preparedness and caregiving self-
efficacy, compare the effectiveness of two strategies for
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diagnostic evaluation and management after ADRD screen-
ing, and examine congruence between patient–family
member dyad outcomes among the three randomized
groups. As shown in Fig. 1, the COADS trial will enroll
1800 patient–family member dyads from primary care
clinics in Indiana, USA. These dyads will be randomized
into three groups (n = 600 per group). Older adults in the
first group will be screened for ADRD at baseline coupled
with disclosure of the screening results to the dyad. If the
patient screens positive, the dyad will receive a list of local
resources for follow-up diagnostic care and disclosure of
positive screening results to the patient’s primary care phys-
ician (the Screening Only group); older adults in the second
group will be screened for ADRD at baseline coupled with
disclosure of the screening results (as above) and, if they
screen positive, a referral to a dementia collaborative care
program (the Aging Brain Care (ABC) Program) for diag-
nostic evaluation and subsequent care if ADRD is diag-
nosed (the Screening Plus group). The ABC Program
conducts diagnostic evaluations and delivers collaborative
care management to patients diagnosed with ADRD and
their family caregivers and is described in detail below.
Older adults in the third group will not be screened at base-
line and family members are given no information about
cognition (the control group). In this group, we will ob-
serve, through surveillance of the electronic health record
of the participant, any screening or incident diagnoses of
ADRD that occur as part of routine care, including the
Medicare AWV. At the end of follow-up (24months), we
will screen the older adults in this group and conduct an
interview with the family member to detect possible cogni-
tive impairment in the participant. The COADS trial will
measure the primary and secondary outcomes at baseline
and at 6, 12, 18 and 24months. Consent, enrollment, data
collection, and ADRD screening (if in a screening arm) will
be obtained face-to-face in the primary care clinic or by
telephone.
This study protocol has followed the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Guidelines (Additional file 1). The trial will be conducted
and reported according to the reporting of pragmatic trials,
an extension of the Consolidated Standards of Reporting
Trials (CONSORT) statement. The study has been ap-
proved by the Institutional Review Board of Indiana
University (IRB no. 1705649205). The COADS trial is regis-
tered with ClinicalTrials.gov (NCT03300180).
Setting and study population
Patient–family member dyads for the COADS trial will be
recruited from Eskenazi Health (EH) primary care sites and
primary care sites affiliated with Indiana University Health
(IUH). Recruitment will occur via the Indiana University
Practice-Based Research Network, which covers research
recruitment in all primary care practices affiliated with EH
Fig. 1 Recruitment, enrolment, and measures for the Caregiver Outcomes of Alzheimer’s Disease Screening (COADS) trial. ABC Aging Brain Care
(Program), ADRD Alzheimer’s disease and related dementias, base baseline, EMR electronic medical record, HRQOL health-related quality of life,
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly, PC primary care, PCP primary care physician, Rx prescription
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and IUH [37]. We have long-standing relationships with
these sites which serve diverse populations of insured and
uninsured patients throughout the Indianapolis metropol-
itan area and central Indiana. EH is the third largest safety
net health system in the USA. We will recruit from primary
care practices (all of which are Federally Qualified
Health Centers) in Indianapolis that are associated
with EH. We will have access to recruit from over
20 primary care practices in central Indiana that are
affiliated with IUH, which includes more than 200
primary care providers. We will also use the Indiana
University Practice-Based Research Network as our
recruitment method [37]. Data generated by the In-
diana University Practice-Based Research Network is
collected and stored in the Indiana Network for
Patient Care, which serves as the central Indiana
Regional Health Information Exchange (IHIE) [38].
Our study team has long-standing relationships with
the clinical sites participating in this trial, and has
conducted numerous research activities and projects
within their primary care practices [19, 39–50].
Eligibility
The target population is dyads formed by: 1) an adult
aged 65 or older without a diagnosis of ADRD; and 2) a
family member or legal health care power of attorney
whom the patient identifies as someone who would pro-
vide care for them if they needed it. Eligibility of patients
will be established through screening the Indiana Net-
work for Patient Care database and by assessments
conducted by the research assistants face-to-face or via
the telephone.
Inclusion criteria
The following inclusion criteria are employed for the pa-
tients: ≥65 years of age, have had at least one visit to the
primary care practice within the last year, are able to
provide informed consent, and can communicate in Eng-
lish. Family members serving as study partners must be
≥21 years of age, identified by the patient as the person
most likely to provide care for them if needed, able to
provide informed consent, able to communicate in
English, and live within a 50 mile radius of the patient.
Study partners who are not family members must meet
family member inclusion criteria and be the legal health
care power of attorney.
Exclusion criteria
Dyads will not be eligible if the patient has a diagnosis
of ADRD (which we will identify via the Indiana Net-
work for Patient Care by medical record review of the
10th Revision of the International Statistical Classifica-
tion of Diseases and Related Health Problems (ICD-10)
codes) [37], evidence of a prescription for cholinesterase
inhibitors or memantine (medications used to treat
patients with ADRD), has a serious mental illness (e.g.,
bipolar or schizophrenia as determined by ICD-10 code),
is an established patient in the EH ABC Program, or is a
permanent resident of a nursing facility. Dyads will also
be excluded if the proposed study partner self-reports a
serious mental illness (i.e., bipolar or schizophrenia as
determined by ICD-10 code), has a diagnosis of ADRD
determined by self-report, or is a nonfamily member
who does not have legal health care power of attorney
for the patient.
Recruitment
Patients will be contacted first by letter to inquire about
their interest in participating or approached in clinic at a
visit to assess interest and eligibly. If they are interested,
the team member then asks for the name and contact
information of a family member and additionally re-
quests permission to call the family member to assess if
they are also willing to enroll. Given that not all patients
will require the assistance of a caregiver during the study
or have a person identified as a caregiver, we want to
identify the person most likely to assume that role when
patient needs arise.
Based on the literature and our own pilot data, we an-
ticipate approaching approximately 3500 dyads to enroll
1800 dyads. Rolling enrollment will take place over 22
months with an average monthly enrollment of 80
dyads. The COADS trial will reduce loss to follow-up
for longitudinal assessments by engaging the dyads every
6 months throughout the study (at 6, 12, 18 and 24
months), including keeping the assignment of research
staff and participants consistent at each outcome assess-
ment, sending reminder letters, and sending birthday
cards signed by the study team. This strategy has pro-
duced <1% loss to follow-up in the pilot study.
Randomization
The unit of randomization will be the patient–caregiver
dyad. Dyads will be randomly assigned in 1:1:1 ratio to
one of three groups (Screening Only or Screening Plus
or control) and stratified by recruitment site to control
for institutional effects and styles of different primary
care providers.
Study statisticians will use a computer-generated
randomization scheme (random block sizes of 3 or 6)
stratified by the patient’s health care system (EH ver-
sus IUH) to assign dyads rather than providers or
clinics to one of three groups to minimize the effects
of unmeasured case mix differences and clinic-level
clustering. Based on data from the COADS pilot and
the literature, the risk for ‘spillover’ from having par-
ticipating clinics treat both intervention and usual
care patients is likely small [48].
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Description of the intervention
For both screening arms, we will use the Mini-Cog or
the Memory Impairment Screen Telephone version
(MIS-T) as our ADRD screening instrument [51, 52].
These instruments were selected to allow for flexibility
in mode of screening and because both instruments
demonstrate validity in primary care, are short and prac-
tical (4–5min to complete with excellent inter-rater reli-
ability), and have a positive likelihood ratio of 5 or
higher [51–53]. The MIS-T has a total score from 0
point to 8 points. A cut-score ≤5 has 85% sensitivity and
86% specificity for dementia with a positive predictive
value of 52% in a setting with a dementia prevalence of
15% [27, 51–53]. The Mini-Cog has a total score of 0–5
and takes 3–5min to administer. A cut-score ≤2 has
76–99% sensitivity and 89–93% specificity for dementia
with a positive predictive value of 32% [54–57]. The
ADRD screening will be administered to the patient by
the study research assistants after the dyad consents and
is randomized into one of the two screening arms.
Screening Only
Dyads randomized to the Screening Only group will re-
ceive a letter that will include the results of the patient’s
ADRD screening results provided in lay-language. For
patients who score 6–8 on the MIS-T or ≥3 on the
Mini-Cog, both the patient and family member will re-
ceive a letter indicating that they performed “within nor-
mal range”, but also will advise that if they have any
concerns they should talk with their primary care phys-
ician. If the patient’s score is ≤5 on the MIS-T or ≤2 on
the Mini-Cog, the letter states, “your score (or the
patient’s score) on the test was lower than we would
expect. This indicates that you may be having a problem
with your thinking or memory”, and will encourage the
patient and family member to discuss this with the pa-
tient’s primary care physician at the earliest possible
time with the suggestion they ask about additional cog-
nitive tests to identify possible causes. The primary care
physicians of patients who screen positive in the Screen-
ing Only group will also receive a brief note of the pa-
tient’s screening test performance via the electronic
health record system.
Screening Plus
Patients and family members randomized to the Screen-
ing Plus group receive the same letters described above,
with additional electronic health record system notifica-
tion to patient’s primary care physician upon a positive
screen result. If the patient scores ≤5 on the MIS-T
or ≤2 on the Mini-Cog, the letter will also indicate that
the dyad will be receiving a call from the ABC Program
along with the name and contact number for an ABC
Program care coordinator (CC). All referrals from the
study to the ABC Program will occur within 48 h of the
positive screening result. Only dyads where the patient
screens positive will be referred to the ABC Program.
The patient’s primary care physician is also informed of
the ABC Program referral and provided with informa-
tion about the ABC Program, including the clinic’s pro-
viders and a general overview of what a follow-up visit
would include for a dyad.
The ABC Program conducts diagnostic assessments
and performs collaborative care management between
the dyad, aging brain specialists, and the patient’s pri-
mary care physician. It includes a medical (MD, RN, and
PharmD) and nonmedical (social workers, public health
workers, and CC assistants) [46] workforce. This is a
collaboration that is supported by evidence-based assess-
ment tools (e.g., The Healthy Aging Brain Care Monitor)
[58] and a technology platform (e.g., a mobile office and
the care coordination electronic Medical Record Aging
Brain Care (eMR-ABC) software) so care can be deliv-
ered wherever the person and their caregiver needs it
[59]. Through its three phases, the program is targeted
to comanage or support the practice behavior of primary
care clinicians, enhance self-management skills of both
the patient and caregiver, and maximize the coping
behavior of the patient and the informal caregiver. By
design, the previously tested program protocols lead to
individualized and patient-centered profiles of actual in-
terventions for individual patients and their informal
caregivers [44, 50].
In phase 1 (initial assessment), a CC conducts a biop-
sychosocial needs assessment by telephone upon enroll-
ment and schedules a clinic visit for a dyad for follow-up
diagnostic testing. The telephone call includes a demo-
graphic and psychosocial interview focused on achieving
problem identification using standardized assessment
tools and eMR-ABC. Results from this assessment in-
form the clinic visit when neurological examination and
neuropsychological testing are conducted. Also, at the
clinic visit, the care team focuses on problem clarifica-
tion and reviews the assessment findings, the medical
record and medication lists, any diagnostic testing, any
brain imaging results, and functional details of the as-
sessment to determine the presence or absence of a
likely dementia diagnosis, identifying any reversible and
comorbid conditions. After the first visit and review of
all findings from prior data, the care team creates an
initial plan and identifies areas needing further assess-
ment at a possible home visit.
In phase 2 (collaborative care plan development), the
diagnostic report and individualized care plan is created
and reviewed with the patient and the family caregivers.
A summary is also sent to the patient’s primary care
team. After phase 1 is completed, any urgent medical,
behavioral, and psychological issues are addressed via
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consultation with specialists (e.g., geriatricians and neu-
rologists) and/or the primary care physician as needed.
The ABC team will map out a proposed care plan and
schedule a home visit to review findings, discuss identi-
fied problems and propose a collaborative plan. During
the home visit, the team reviews the identified problem
list and seeks input from the dyad regarding the content
of the list and the priority level of those problems, ad-
dressing first the issues felt to be most important by the
patient. From this resulting consensus, the CC discusses a
proposed individualized care plan, explains the diagnosis
and natural history, implements appropriate care proto-
cols, reviews, explains, and distributes the corresponding
educational handouts for the dyad, and connects patients
and family caregivers to in-home services and community
resources as needed.
In phase 3 (follow-up phase), the CC team will continue
to interact with the dyad face-to-face at their home or via
telephone or email/mail. Interaction intensity will be
dictated by the care plan, presenting needs, and circum-
stances. During these interactions, the CC will answer any
questions generated from previous visits, collect dyad
feedback, have the caregiver complete a brief assessment
to identify need for specific care protocols, and facilitate
the caregivers’ participation in an array of community
services that are available in central Indiana. The CC will
reconcile medications and review medication adherence at
the home visits. Medication questions will be referred to
the patient’s primary care physician. Throughout the
duration of the follow-up phase, the team will continue to
work with the dyad and the patient’s primary care phys-
ician to monitor, implement, and adjust the individualized
care plan, as necessary.
Description of the control
Patients in dyads who are randomized to the control
arm (no screening) will not be screened at baseline.
Similar to the design of cancer screening trials [60], this
group will undergo active surveillance throughout the
study via electronic health records to monitor any
ADRD screening in primary care (routine or AWV), new
diagnoses of ADRD, and new prescriptions for antide-
mentia medications. At the 24-month outcome assess-
ment, we will administer the MIS-T or Mini-Cog to the
patient and the short form of the Informant Question-
naire on Cognitive Decline in the Elderly (short
IQCODE) [61] to the family member to determine the
patient’s cognitive status, and to differentiate which pa-
tients in this group may have impairment. This approach
will allow comparison of family members in each of the
three arms, by group, by patient screening status (posi-
tive versus negative), and by cognitive status (impaired
versus not impaired).
COADS was designed with these three conditions, two
of which include pathways for diagnostic assessment and
care, for two main reasons: 1) to ensure that postscreen-
ing evaluations and care would not confound the effects
of testing the impact of screening overall; and 2) to con-
firm that the evaluation of an ADRD screening program
on outcomes should be consistent with previous screen-
ing studies in other conditions that found that discon-
necting screening from a subsequent diagnostic process
and care program reduces the impact of screening on
the burden of the target condition [62].
Primary and secondary outcome measures
The primary outcome measure is family member health-
related quality of life. Secondary measures include family
member depressive and anxiety symptoms, caregiving
preparedness, caregiving self-efficacy, and patient de-
pressive and anxiety symptoms. Primary and secondary
outcome measures will be assessed at baseline and at 6,
12, 18 and 24months by blinded research assistants.
Health-related quality of life
We will use the Medical Outcomes Study Short Form
Health Survey 36 (SF-36) to determine the family mem-
bers’ and patients’ health-related quality of life at each
time point [63]. The SF-36 is a general population in-
strument that measures health-related quality of life and
mental, physical and social functioning [64, 65]. It in-
cludes one multi-item scale that assesses the following
eight health concepts: physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,
role-emotional and mental health. These concepts are
aggregated into a physical component summary (PCS)
and a mental component summary (MCS). Changes that
differ between groups by ≥2 points on a scale of 0 to
100 have been shown to be clinically or socially mean-
ingful. Higher SF-36 scores indicate better health func-
tioning [64]. The SF-36 is psychometrically sound and
has been used extensively in older adults and caregivers
of older adults with and without ADRD [66, 67].
Depressive and anxiety symptoms
We will use the Patient Health Questionnaire 9 (PHQ-9)
[68, 69] and the Generalized Anxiety Disorder Scale
(GAD-7) [70, 71] to determine the impact of ADRD
screening on family members’ and patients’ mood and anx-
iety at each time point. The PHQ-9 is a nine-item depres-
sion scale with a total score from 0 to 27, and the GAD-7 is
a seven-item anxiety scale with a total score from 0 to 21.
Both of these scales are derived from the Patient Health
Questionnaire, have good internal consistency, test–retest
reliability, as well as convergent, construct, criterion, pro-
cedural, and factorial validity for the diagnosis of major
depression and generalized anxiety disorder [69, 71]. In our
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previous studies conducted in primary care settings, the
mean PHQ-9 scores ranged from 3.8 (SD = 5.1) to 4.4
(SD = 5.6), and the mean GAD-7 scores ranged from 2.7
(SD = 3.2) to 3.2 (SD = 3.5) [66]. In a study conducted by
our group, the PHQ-9 was shown to be a valid measure of
stressful events, both related and unrelated to caregiving
[72]. Each of the above measures (SF-36, PHQ-9, and
GAD-7) has been shown to be sensitive to change over
time [66, 69–71].
Caregiver preparedness
Caregiver preparedness refers to how ready family mem-
bers perceive they are for the tasks and demands of caregiv-
ing such as providing physical care and emotional support
to the patient or dealing with the stress of caregiving if they
were to experience a transition in role [73, 74]. Family
members who report a high level of preparedness for
caregiving have been shown to experience less worry and
decreased levels of depression [75, 76]. In contrast, family
members who perceive themselves as being inadequately
prepared are prone to greater levels of burden [77]. Pre-
paredness for caregiving is associated with generally lower
levels of caregiver strain and has a broad effect on multiple
indicators of quality of life and total mood disturbance [75–
77]. Although previous claims in the literature have stated
that earlier identification of ADRD through screening can
help prepare caregivers, no data exist to support this claim
[12]. Our trial will test if earlier identification of ADRD
through screening impacts caregiver preparedness.
We will use the Preparedness for Caregiving Scale [77] to
measure the impact of ADRD screening on family member
preparedness. The Preparedness for Caregiving Scale con-
sists of eight items that asks family members how well pre-
pared they believe they are for multiple domains of
caregiving. Responses are rated on a five-point scale with
scores ranging from 0 (not at all prepared) to 4 (very well
prepared). The scale is scored by calculating the mean of all
items answered with a score range of 0 to 4. The higher the
score, the more prepared the caregiver feels for caregiving;
the lower the score, the less prepared the caregiver feels. In-
ternal consistency of this scale has been reported as excel-
lent with alpha scores ranging from 0.88 to 0.93 [75, 78].
Caregiver self-efficacy
Research suggests that self-efficacy may be an import-
ant construct to understanding how family members
of older adults cope with the role transition to a care-
giver and the subsequent challenges and demands of
providing care [79]. Among family caregivers of older
adults with ADRD, Aneshensel and colleagues found
that caregivers’ self-efficacy, particularly their sense of
mastery and control about their caregiving role, had a
direct and positive effect on reducing caregiver de-
pression over time [80, 81].
The COADS study utilizes the Revised Scale for Care-
giving Self Efficacy [82] to measure the impact of ADRD
screening on caregiver self-efficacy. The scale is a 15-item
scale that evaluates family members’ capacity in relation
to the caregiving role, more specifically with regard to
obtaining respite from caregiving by the involvement of
family and friends (e.g., asking a friend or family member
to stay with the patient for a day to take a break). The
scale also inquires about family members’ perceived con-
trol over disturbing thoughts that may arise about the
caregiver role (e.g., unfairness of having to manage this
caregiving situation) and their response to the relative’s
disruptive behaviors (e.g., responding without raising your
voice when your relative interrupts your activities repeat-
edly). Respondents rate their degree of self-efficacy on a
scale from 0 (absolutely incapable) to 100 (fully capable).
Pearson correlation coefficients between the overall scale
and the three specific dimensions ranged from 0.66 to
0.73 (P < 0.001). The alpha coefficient for the overall scale
was 0.86 [79–82].
Other measures
The COADS study additionally collects data from pa-
tients’ electronic health records to assess if and when
they undergo any ADRD screening (outside of the
COADS trial) as part of their routine primary care, an
AWV, or specialty care. Data generated as part of an en-
counter by a provider who practices within EH and IUH
are stored in the Indiana Network for Patient Care,
which serves as the central IHIE and is available to clin-
ical researchers to assess health events and utilization
[37]. For dyads who are not randomized to screening at
baseline (control group), cognition will be assessed at
the end of the study at the 24-month assessment.
Patients will be screened with the MIS-T or Mini-Cog,
and the IQCODE is administered to all family members.
The IQCODE screening tool is a short questionnaire de-
signed to assess cognitive decline and dementia in older
adults, informed by a relative; the 16 questionnaire items
are summed and divided by 16. Using IQCODE cut-offs
commonly employed in clinical practice (3.3–3.6) the
sensitivity and specificity of IQCODE for the diagnosis
of dementia is generally above 75% in community-
dwelling older adults [83]. Information obtained from
the MIS-T, Mini-Cog, and IQCODE results will allow
for comparison of family member responses between the
three groups sorted by the patients’ cognitive status.
Data monitoring
The Data Safety Monitoring Plan (DSMP) for this trial will
be monitored by the Principal Investigator and a five-
member Data Safety and Monitoring Board (DSMB). The
DSMB charter contains a detailed list of the DSMB re-
sponsibilities. The DSMB will act in an advisory capacity
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to the Institutional Review Board and National Institute
on Aging Program Official to monitor participant safety,
evaluate the progress of the study, and review procedures
for data management and analysis, maintaining the confi-
dentiality of data, and the quality of data collection.
Potential adverse events that will be monitored in the
COADS study include patient or family member death,
any event that is life threatening or places the participant
at immediate risk of death, requires or prolongs
hospitalization, causes persistent or significant disability
or incapacity, or another condition which investigators
judge to represent significant hazards. Developments in
this realm will be monitored on an ongoing basis by the
COADS research manager and discussed weekly among
the research team. All adverse events and unanticipated
problems will be reported to the study Principal Investi-
gator within 24 h of discovery. If unanticipated serious
adverse events occur (i.e., not listed in the DSMP) and
are related to the intervention they will be reported
within 48 h.
Data collection
Data for the COADS trial will be collected at baseline
and at 6, 12, 18 and 24 months. Following the confirm-
ation of eligibility and completion of informed consent,
all family members and patients in each of the three
arms will complete the baseline assessment, which in-
cludes the SF-36, PHQ-9 and GAD-7. Family members
at baseline will also complete the Caregiver Preparedness
Scale, Caregiving Self-efficacy Scale, and the Oberst
Caregiving Burden Scale (at baseline only) [84, 85]. Data
will be collected face-to-face at the clinic or via tele-
phone; data will also be obtained via electronic health
record review. Research staff who administer follow-up
assessments will be blinded to dyad intervention status
and will be trained to read all questionnaires verbatim,
without commentary. In addition to the primary and
secondary measures, the study will collect social and
demographic data on all patients and family members,
including age, sex and race. The assessments will also
record the relationship of the family member to the pa-
tient, the frequency and type of contact with the patient,
geographic distance from the patient, education level,
annual income, self-reported health status, and whether
or not they have knowledge as to whether the patient
has ever been screened for ADRD as part of routine pri-
mary care, an AWV, or a community screening event.
Additional patient descriptive data will be obtained from
the recruitment site databases and the Indiana Network
for Patient Care including, but not limited to, comorbid-
ities. All survey data will be entered into a database
using Research Electronic Data Capture (REDCap), a
secure web-based application available through our
Clinical and Translational Science Institute.
Timeline
The recruitment of patients began on 15 October 2018
and is expected to be finalized by August 2020. All data
collected from recurring outcome assessments is expected
to be collected by 2022. The data analysis, writing of sci-
entific manuscripts, and submissions to peer-reviewed sci-
entific journals will occur from 2020 to 2023.
Analysis plan
Comparison of baseline characteristics
The first examination will analyze univariate distributions
of continuous variables to detect any potential violations
of assumptions to our planned parametric methods of
analysis. Variables will be transformed as needed to ensure
normal distribution assumptions are met. Nonparametric
methods will be used if transformations are inadequate.
Demographic characteristics will be compared among the
groups to evaluate whether the randomization effectively
balances the dyads. We will use Chi-squared tests or
Fisher’s exact tests to compare the frequencies of categor-
ical variables. Analysis of variance (ANOVA) or its non-
parametric alternative, the Wilcoxon rank sum test, will
be used to compare the distribution of continuous vari-
ables among the groups. All analyses will be conducted
using SAS 9.4 (SAS Institute, Carey, NC, USA).
Comparison of outcomes
Since our randomized controlled trial is randomizing pa-
tients in dyads to ADRD screening or no screening, our
planned analyses will utilize multilevel mixed-effects
models to capture repeated measures from both patients
and family members. Multilevel mixed-effects models will
be used to examine differences in SF-36 scores, PHQ-9 or
GAD-7 for both patients and family members using
dyadic analytic approaches comparing dyads in the two
screening groups (Screening Only and Screening Plus) to
those in the no-screening (control) group. Repeated SF-
36, PHQ-9 or GAD-7 scores from both patients and fam-
ily members will be included as the outcome variables
with participant type (patient or family member), group
(Screening Only and Screening Plus versus control), time,
and interaction between groups and time as independent
variables [86]. We will use a multilevel variance–covari-
ance matrix in the mixed effects models to account for
two sources of potential correlations: 1) correlations from
measures obtained from the same individual over time (an
autoregressive correlation will be used); and 2) correla-
tions within a dyad between a patient and his/her family
member (a compound symmetry structure will be used
for the intra-dyad correlation). Parameter estimation and
hypothesis tests for the mixed-effects models will be con-
ducted using the maximum likelihood approach that pro-
vides robust estimation under the missing at random
mechanisms [87]. A significant interaction between group
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and time would indicate differences in changes of SF-36,
PHQ-9 or GAD-7 over time between the screening groups
and the no-screening group. In the absence of significant
interactions, significant main group effects would suggest
differences in the outcome between groups at all follow-
up time points. We will use a linear contrast for SF-36,
PHQ-9 or GAD-7 from family members to compare these
outcomes in the combined screening groups (Screening
Only and Screening Plus) versus the no-screening group
(control) at 24months. We will also include additional co-
variates in the mixed-effects models to determine whether
family member characteristics (e.g., relationship to patient,
frequency or types of contact) and knowledge of screening
are associated with the outcome measures.
The study will also assess the impact of ADRD screening
on family members’ caregiving preparedness and caregiving
self-efficacy using mixed-effects models with the Caregiver
Preparedness Scale and the Revised Scale for Caregiver
Self-Efficacy scores collected at baseline and at 6, 12, 18
and 24months as the outcome variables, and group
(Screening Only and Screening Plus versus control), time,
and interaction between group and time as independent
variables. Linear contrasts will be used to compare pre-
paredness and caregiver self-efficacy scores in the combined
screening groups versus the no-screening group at 24
months. We will also evaluate potential interactions be-
tween patients/family member characteristics and variables
associated with increased level of caregiver preparedness
and self-efficacy over time.
To measure the impact and compare strategies for evalu-
ation and treatment postscreening, this study will compare
quality-of-life measures, caregiver preparedness, caregiving
self-efficacy, and depression and anxiety symptoms as re-
ported from family members in the Screening Only group
to those in the Screening Plus group. The screening groups
differ by the amount of postscreening contact, therefore
possible outcome differences between these two groups will
be analyzed using multilevel mixed-effects models, similar
to the approach described in detail above. Separate mixed-
effects models with SF-36, Caregiver Preparedness Scale,
Revised Scale for Caregiver Self-Efficacy, PHQ-9 or GAD-7
scores collected at baseline and at 6, 12, 18 and 24months
from family members will be used as the outcome variables.
Screening group (Screening Only versus Screening Plus),
time, and interaction between group and time will be used
as independent variables. Linear contrasts will be used to
compare all scale scores between the two screening groups
at 24months.
Sensitivity analyses for the impact of refusals and other
sources of missing data
We will compare patient and family member character-
istics between 1) those who complete at least one or
more follow-up assessment(s) after baseline and 2) those
who did not complete any assessment beyond baseline
due to refusal or other reasons. Significant variables de-
tected from these comparisons will be included in the
mixed-effects models for the primary and secondary out-
comes as covariates to control for potential bias from
those who did not complete any follow-up outcomes.
Under the missing at random assumption, results from
the mixed-effects models will remain unbiased if the var-
iables contributing to the missing data are included as
covariates in the models. We will also perform additional
sensitivity analyses to examine whether our analyses are
impacted by the missing at random assumption using
the selection model approach under an informative
missing mechanism [87].
Sample size and statistical power analysis
For the models examining the impact of ADRD screen-
ing on caregivers’ quality of life, mood, anxiety, pre-
paredness and self-efficacy, we assume a base correlation
of 0.2 and a decay rate of 0.8 in a linear exponent auto-
regressive correlation structure for repeated measures
and a continuous time response. We will need to have
540 dyads per group to have complete data at 24 months
in order to achieve 82.6% power to detect a group by
time interaction, with an effect size of 0.24 SD where
there are higher SF-36, lower PHQ-9, lower GAD-7,
higher caregiver preparedness and self-efficacy scores in
the combined screening groups (Screening Only and
Screening Plus) at 24 months compared to family mem-
bers in the no-screening (control) group at 24 months.
Therefore, allowing a loss to follow-up rate of 10% over
the 24months, the study plans to enroll 600 dyads per
group into this study. In order to compare the effective-
ness of the two strategies for diagnostic evaluation and
management after ADRD screening, similar assumptions
are employed regarding the correlation structure for re-
peated measures and, with a 10% attrition rate, there will
be an 83.4% power to detect a significant group and time
interaction, with an effect size of 0.28 SD when compar-
ing family members randomized to the Screening Plus
group to those in the Screening Only group at 24
months. Power estimation was conducted using the
GLMPower procedure in SAS.
Discussion
Although multiple national expert panels who represent
a broad range of stakeholders, including the National
Academy of Science, the National Plan to Address Alz-
heimer’s Disease, and the Affordable Care Act, through
the AWV, have identified early detection of ADRD as a
national priority [12, 15], the USPSTF recommendations
do not currently support screening for ADRD in primary
care [12]. The COADS trial will be the first to examine
the potential benefits or harms of ADRD screening
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specifically on caregivers’ quality of life, mood, anxiety,
preparedness, and self-efficacy. It will also compare the
effectiveness of two strategies for diagnostic evaluation
and management after ADRD screening.
The COADS trial will use an innovative design that is
common in cancer screening trials to create three
groups to compare family member outcomes as a result
of screening and postscreening strategies and to analyze
individual outcomes and congruence between patient–
family member dyad outcomes. It will randomize 1800
dyads into three groups: a Screening Only group, a
Screening Plus group, and a control group. This ran-
domized design will allow us to investigate the relation-
ship between patient exposure to ADRD screening and
family member outcomes as a result of the exposure,
with minimum confounding bias. This study design will
also produce the necessary data to examine if the risks
and benefits of screening experienced by patients align
or diverge with those of family members.
Having two different postscreening approaches (rou-
tine primary care versus dementia collaborative care)
and conducting real-world surveillance of any screening
in the no-screen group will also separate the impact of
the screening event from the follow-up care and allow
us to test organized screening (Screening Only and
Screening Plus groups) versus usual care (no-screen con-
trol group). This design will allow us to test the effect of
screening on its own and to test two different strategies
for implementing a postscreening policy. Although
coupling screening with diagnostic services and care is
consistent with the World Health Organization’s Princi-
ples and Practices of Screening for Disease [88], we
recognize that dementia collaborative care is not avail-
able throughout the USA and that it may confound the
effects of screening versus no screening if those who
screen positive are only referred to a collaborative care
program. This innovative aspect of our design will allow
us to test if collaborative care as part of screening is an
essential part of any ADRD screening program and if
disconnecting screening from a subsequent diagnostic
process and care program reduces the impact of screen-
ing on the burden of the target condition.
The present study has some limitations. The first
and most significant threat to the success of the
COADS trial may be recruitment of both members of
the patient–family member dyad. Some older adults
will have no family that can participate, and some
family members may be unwilling to view themselves
as potential future caregivers. The second limitation
is that some patients eligible for this study and ran-
domized to the no-screen (control) group may be
screened for ADRD as part of routine primary care.
A third limitation is that dyads who are in the
Screening Plus group may refuse to seek follow-up
from the ABC Program if they screen positive. To as-
sess and prepare for these possible limitations, we
have: 1) conducted a large pilot to assess the number
of potential dyads who both agree to consent; 2)
piloted the protocol and measures; 3) collected pilot
data from dyads to assess knowledge about the pa-
tient’s screening status either as part of research or
during routine primary care; 4) conducted a feasibility
study using data from our regional health exchange to
measure counts of screening or AWVs; and 5) col-
lected pilot data of how many patients refuse diagnos-
tic assessment following a positive screen and adjusted
our sample size to account for this. In our pilot study,
82% of patient–family members dyads approached for
the COADS pilot agreed to participate. And, although
screening in routine primary care may confound the
impact of screening on family members, the preva-
lence of the AWV is still small and our design is
sound and pragmatic as it mirrors what is likely to
occur in primary care. As previously noted, in 2014
only 14% of eligible Medicare beneficiaries received an
AWV [33]. In preparation for this study, we found that
among a sample of ~44,000 Medicare beneficiaries in
the EH and IUH population <8% had a documented
AWV in 2016. Lastly, although randomized trials are
the gold standard for evidence-based decision making
in medicine, they can have important limitations as a
basis for screening policies. First, screening policy de-
velopment demands information about long-term ben-
efits and harms because these policies generally
pertain to interventions conducted over an individual’s
healthy lifetime. We have extended our outcome to 24
months, but the long-term outcomes generated by a
typical population-based screening program may not
be fully realized for 5–8 years [89, 60].
In summary, as the number of patients with ADRD
increases, so will the number of family caregivers. Al-
though the need for early detection of ADRD is fre-
quently debated as important care for older adults,
this includes the need to support their family mem-
bers to prepare for caregiving needs. The effects of
routine screening on reducing the burden of ADRD
and improving outcomes for family caregivers are un-
known. The COADS trial will be the first of its kind
to test the impact of ADRD screening and postscre-
ening care pathways on family members using longi-
tudinal data that is collected synchronously with
patient outcome data. Following dyads after screening
in diverse primary care settings including a large seg-
ment of minority, underprivileged, and rural popula-
tions will directly inform the National Plan to
Address Alzheimer’s Disease, the USPSTF and other
organizations regarding their ADRD screening and
early detection policies.
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Trial status
This study received ethical approval from the Indiana
University Institutional Review Board on 20 July 2017.
The first dyad was enrolled on 15 October 2018. To
date, 868 dyads (1736 participants) have been random-
ized so far. We are still recruiting patients and plan to
close the recruitment at the end of 2020.
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1186/s13063-019-4029-5.
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